Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 1124-1128, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (13)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pesce, A. J.
Right arrow Articles by Kotagal, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pesce, A. J.
Right arrow Articles by Kotagal, U.
Related Collections
Right arrow National Academy of Clinical Biochemistry
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 1998;44:1124-1128.)
© 1998 American Association for Clinical Chemistry, Inc.

NACB Symposium

Standards of laboratory practice: theophylline and caffeine monitoring

Amadeo J. Pescea, Mitchell Rashkin, and Uma Kotagal

Departments of Pathology and Laboratory Medicine, Internal Medicine and Pediatrics, University of Cincinnati Medical Center, P.O. Box 670714, Cincinnati, Ohio 45267.
a Author for correspondence. Fax 513-558-4176; e-mail amadeo.pesce{at}UC.edu.

Theophylline is used in the treatment of asthma and chronic obstructive pulmonary disease. The use of theophylline has declined with the advent of potent steroid inhalants. Because of the therapeutic index of this drug, monitoring of theophylline concentrations in plasma is essential. Monitoring should be done on trough specimens after steady-state has been reached. Non-steady-state concentrations may be indicated in selected situations. Caffeine is used to treat apnea of the newborn because of its low toxicity. Monitoring is often by clinical effect. Monitoring of serum concentrations should be performed in cases where there is no clinical response or if there is suspected toxicity.




The following articles in journals at HighWire Press have cited this article:


Home page
 NEJMHome page
B. Schmidt, R. S. Roberts, P. Davis, L. W. Doyle, K. J. Barrington, A. Ohlsson, A. Solimano, W. Tin, and the Caffeine for Apnea of Prematurity Trial Group
Long-Term Effects of Caffeine Therapy for Apnea of Prematurity
N. Engl. J. Med., November 8, 2007; 357(19): 1893 - 1902.
[Abstract] [Full Text] [PDF]

Home page
 NeoReviewsHome page
G. Natarajan, M. Lulic-Botica, and J.V. Aranda
Pharmacology Review: Clinical Pharmacology of Caffeine in the Newborn
NeoReviews, May 1, 2007; 8(5): e214 - e221.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
G. Natarajan, M.-L. Botica, R. Thomas, and J. V. Aranda
Therapeutic Drug Monitoring for Caffeine in Preterm Neonates: An Unnecessary Exercise?
Pediatrics, May 1, 2007; 119(5): 936 - 940.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
B. Schmidt, R. S. Roberts, P. Davis, L. W. Doyle, K. J. Barrington, A. Ohlsson, A. Solimano, W. Tin, and the Caffeine for Apnea of Prematurity Trial Group
Caffeine Therapy for Apnea of Prematurity
N. Engl. J. Med., May 18, 2006; 354(20): 2112 - 2121.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. W. Jenny and K. Y. Jackson-Tarentino
Causes of Unsatisfactory Performance in Proficiency Testing
Clin. Chem., January 1, 2000; 46(1): 89 - 99.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.